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The endoplasmic reticulum (ER) is a principal mediator of signal transduction in the cell, and disruption of its normal function
(a mechanism known as ER stress) has been associated with the pathogenesis of several diseases. ER stress has been demonstrated
to contribute to onset and progression of diabetic retinopathy (DR) by induction of multiple inﬂammatory signaling pathways.
Recent studies have begun to describe the gene expression proﬁle of ER stress-related genes in DR; moreover, genes that play a
protective role against DR have been identiﬁed. P58
IPK was determined to be able to reduce retinal vascular leakage under high
glucose conditions, thus protecting retinal cells. It has also been found by our lab that ER-associated protein degradation factors
exhibit signiﬁcantly diﬀerent expression patterns in rat retinas under sustained high glucose conditions. Future research based
uponthesecollectivegenomicﬁndingswillcontributetoouroverallunderstandingofDRpathogenesisaswellasidentifypotential
therapeutic targets.
1.Introduction
Diabetic retinopathy (DR) is one of the most common
complications of diabetes mellitus. The surge in diabetes
across the globe has led to DR becoming one of the
main causes of blindness. Early clinical manifestations of
DR include apoptosis of retinal pericytes and increase in
permeability of ocular blood vessels. As a consequence,
the protective blood-retinal barrier is broken down, which
further results in microaneurysm, hard exudates, retinal
edema, and minor bleeding. As the disease progresses, the
retinal capillary structure becomes so perturbed that all
normally perfusable areas are eventually lost (Figure 1).
Collectively, these initial clinical changes are diagnosed as
nonproliferative (NP) DR, and the disease is considered to
haveadvancedtoaproliferativestage(PDR)oncerevascular-
ization of the aﬀected region has commenced. At this point,
successive clinical observations include retinal neovascular
proliferation, vitreous hemorrhage, retinal detachment, and
loss of vision. Ultimately, the patient succumbs to blindness.
Interestingly, retinal edema progression to involve the mac-
ula, the central area of the retina, is considered the principal
underlying cause of impaired vision.
Many large-population, multicenter clinical studies have
been performed to identify the most signiﬁcant risk fac-
tors of DR onset and progression. It appears that the
features of diabetes duration, severity of hyperglycaemic
episodes, and elevated blood pressure are directly related
to DR [1–4]. Many DR pathoincidence theories have been
proposed on the basis of these ﬁndings, but none have
y e tt or e s u l ti na ne ﬀective “gold-standard” prophylactic
or therapeutic strategy. At present, the preferred clinical
treatment process is careful maintenance of blood glucose
levels and of blood pressure. Events of neovascularization
and capillary nonperfusion are commonly treated by partial
retinal photocoagulation and pan-retinal photocoagulation,
and macular edema is treated by laser and vitrectomy. At the
latest stages of DR, retinal reattachment surgery is available.
Despiteavastamountofinvestigativeeﬀort,thepathoin-
cidence of DR is not completely understood. Research
ﬁndings have implicated roles for the polyol pathway (aldose
reductase-mediated conversion of glucose to sorbitol) [5,
6], protein kinase C (a known mediator of glucose trans-
port) [7, 8], advanced glycation end products (AGEs,
forming from accumulated glucose), and oxidative stress2 Experimental Diabetes Research
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Figure 1: Fundus photographs (a, c) and retinal ﬂuorescence angiography (b, d) of a patient with proliferative diabetic retinopathy. (a,
b) and (c, d) are images of the same part of the retina. The Fundus photographs revealed widely scattered spots on the retina, which
represent microaneurysms (white star in c). In addition, we observed that the macular foveal reﬂex had disappeared. Yellow-white exudates
were apparent on the temporal area of the macula (white arrow in a). The angiograms were obtained during the arterial phase (b) and
the late arteriovenous phase (d), after injection of dye into an antecubital vein. Retinal neovascularization was observed adjacent to areas
of vascular nonperfusion (white arrow in d). The multiple, tiny ﬂuorescent dots (white star in d) are microaneurysms. The blood-retinal
barrier breakdown manifests as neovascular lesions, which ﬂuoresce brightly and appear blurred as the dye leaks from the vascular lumina
(black arrow in b).
(a by-product of glucose metabolism) [9, 10]. Moreover,
speciﬁc immune/inﬂammatory factors and angioincidence
factors [11, 12] have been implicated in the incidence and
development of DR [13–18].
The incidence of DR has also gained the interest of clin-
ical geneticists interested in determining whether heredity
may signiﬁcantly contribute to DR risk. Indeed, many DR-
susceptibility genes have been identiﬁed by their eﬀorts [19–
21]. Therefore, DR is believed to have a genetic component,
and further research into this mechanism will advance
our overall understanding of DR pathogenesis and help to
identify targets for potential genome-based therapy.
2. ERStress andDR
Recently, studies into the underlying molecular mechanisms
of DR have suggested that endoplasmic reticulum (ER) stress
may play important roles in triggering and maintaining
the disease state. The ER organelle mediates processing of
newly translated proteins, from synthesis and modiﬁcation
to transport. ER stress is the process of the ER adjusting
its function, accelerating or decelerating internal machinery
to eﬀectively meet the precise needs of the cell under
dynamic conditions. For example, the cellular unfolded
protein response (UPR) acts to reduce overall proteinExperimental Diabetes Research 3
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Figure 2: In response to ER stress, Bip separates from the three transmembrane mediators, causing the unfolded protein response to be
activated. Unbound PERK then phosphorylates eIF2α, leading both to inhibition of new protein translation and to induction of the ATF4
transcription factor. ATF4, in turn, activates CHOP gene expression, which then promotes apoptosis and induces the growth arrest and
DNA damage-inducible gene 34 (GADD34). The GADD34 phosphatase dephosphorylates eIF2α, thereby completing a negative feedback
loop. Meanwhile, the unbound IRE1 initiates splicing of the XBP-1 mRNA. Recruitment of the TNF receptor-associated factor3 (TRAF3)
and apoptosis signal-regulating kinase 1 (ASK1) to IRE1 leads to activation of c-Jun amino-terminal kinase (JNK), which in turn activates
c-Jun and mitogen-activated protein kinase (MAPK) and ultimately promotes CHOP activity. Unbound ATF6 is cleaved within the Golgi
apparatus by the site-1 protease (S1P) and the site-2 protease (S2P) to produce an active transcription factor fragment known as ATF6-N,
which in turn activates XBP1 and CHOP; in addition, transcription of ER chaperones and protein disulphide isomerase is increased.
synthesis speed, which in turn decreases protein components
entering into the ER. Subsequently, expression of the ER
molecularchaperonesisupregulated,andtheproteinfolding
function is accelerated in an attempt for the cell to recover
homeostasis. In the event that the UPR becomes too robust
or prolonged [22–25], three ER stress factors are induced
to facilitate quelling of the process. The pancreatic kinase-
(PKR-) like ER kinase (PERK), activating transcription
factor 6 (ATF6) and inositol requiring enzyme 1 (IRE1)
act by binding to the key ER protein immunoglobulin
heavy chain protein/glucose-regulated protein, which has a
molecular weight of 78kDa (Bip/glucose-regulated protein
78 (GRP78)) [26]. However, Bip will dissociate from PERK,
ATF6 and IRE1 under conditions of accumulated unfolded
or misfolded proteins inside the ER. After such dislocation,
the released PERK, ATF6, and IRE1 become activated, and
relevant signal transmission is initiated (Figure 2).
A variety of other factors (over 200 known to date)
participate in the process of ER stress. These factors have
been divided into 11 subclasses, according to their func-
tions: unfolded protein binding, ER protein folding quality
control, regulation of cholesterol metabolism, regulation of
translation, endoplasmic reticulum-associated degradation
(ERAD), ubiquitination, transcription factors, protein fold-
ing, protein disulﬁde isomerization, heat shock proteins
(HSPs), and apoptosis [27].
In 2004, Roybal et al. found that activating transcription
factor 4 (ATF4), which has been identiﬁed as an important
factorofERstress,iscapableofdirectlyincreasingexpression
of the vascular endothelial growth factor (VEGF) gene [28].
Since VEGF itself plays an important role in DR, it is
possible that ER stress acts through this factor to inﬂuence
the pathogenesis of DR. In fact, Ikesugi et al. demonstrated
that glucose deprivation conditions induced ER stress in
retinal pericytes [29], supporting the notion that ER stress
participates in incidence and development of DR. Oshitari
etal.alsofoundthatERstresswasinvolvedinocularvascular
abnormalities in human DR patients [30, 31]. Further
experimental investigation in animal models of diabetes and
oxygen-induced retinopathy (OIR), carried out by Zhang
et al., demonstrated that ER stress was activated in the
aﬀected retinas and indicated that ER Stress is a potential
mediator of retinal inﬂammation in DR [32]. The authors
also demonstrated that ER stress preconditioning could
protect against retinal endothelial inﬂammation through
activation of X-box-binding protein (XBP)1-mediated UPR
and inhibition of NF-κBa c t i v a t i o n[ 33].
ER stress is well known to elicit induction eﬀects on
inﬂammatory factors, and inﬂammation is believed to play
ac r i t i c a lr o l ei nD R ;t h u s ,m a n yr e s e a r c h e r sa r ec u r r e n t l y
exploring the eﬀects of ER stress on DR via the actions of4 Experimental Diabetes Research
inﬂammatory factors [34]. Our laboratory also focuses on
this mechanism of DR.
3.IdentifyingDR-Susceptibilityand
DR-ProtectiveGenes
The bulk of research on DR hereditary factors performed
to date has focused on patients with preexisting illness
(i.e., diabetes), complicating the discovery of true DR-
susceptibility genes. Yet, it has been clearly observed that
the occurrence and severity of DR in diabetic patients varies
amongindividuals.SomepatientsdevelopDRrelativelysoon
after their diabetes diagnosis, while others do not develop
DR for decades. In the same sense, some cases of DR are
mild, while others are severe. Neither the aggressiveness
nor severity of DR have been related to control of blood
sugar levels or extent of loss of control, further indicating
an underlying role for genetic susceptibility. Therefore,
it appears that some diabetic patients have an inherent
resistance to developing the DR complication or are better
equipped to limit its pathogenesis.
It has been estimated that up to 20% of patients who
have suﬀered from diabetes for 20 years remain free of the
DR complication [35]. Since there are no medicines available
whichcaneﬀectivelycontrolDRandmitigateitsprogression,
it can be concluded that expression of a particular gene or
set of genes in these DR-resistant patients can help to protect
againstdiabetes/glucose-relatedinjurytoretinalvessels.Even
if these genes do not protect patients from DR over their
entire lifetime, they may substantially delay onset or lessen
severity of DR. Therefore, identiﬁcation of these genes and
gaining a detailed understanding of their expression patterns
will likely lead to development of new therapeutic targets for
g e n e t i c - b a s e dD Rt r e a t m e n t .
On the basis upon previously published study designs for
detecting genes associated with a disease state [36, 37], we
chose a cohort of Type 2 diabetes patients (n = 59) with
long-standing diagnosis (20 years or more). These patients
were divided into two groups: not complicated by DR
(normal) and complicated by DR. Gene expression analysis
was performed by microarray (GeneChip human genome
U133 plus 2.0; Aﬀymetrix, Santa Clara, Calif, USA), and
statistically signiﬁcant diﬀerences in expression proﬁles were
determined by comparative analysis among the two groups.
Careful analysis of the enrolled patients’ demographics led
to exclusion of 22 patients from the normal group and 37
patients from PDR group. From the remaining patients, 20
were selected from each group, and venous blood samples
were obtained for total RNA extraction. The RNAs of six
patients from each group were preferentially selected to
conduct gene chip detection. We found that diabetic patients
without DR complication presented with 173 overexpressed
genes (P<0.05), compared to the PDR group [38]. These
diﬀerentialexpressionresultswereconﬁrmedbyquantitative
PCR.
Thereafter, the functions of these 173 genes were ana-
lyzed, and it was found that 46 were related to protein
degradation and structure modiﬁcation. In addition, several
factors known to be involved in the ER stress process were
also found. Thus, we concluded that these genes that were
suppressed in PDR patients may represent genes that provide
ap r o t e c t i v ee ﬀect against DR.
4. The Role of P58IPK inDR
One of the diﬀerentially expressed genes in our study of non-
DR diabetic patients versus PRD-aﬄicted diabetic patients
that piqued our interest was P58IPK.T h i sg e n ee n c o d e sa
58kDa inhibitor of the interferon-induced double-stranded
RNA-activated protein kinase (also known as DNAJC3) and
is a member of the Hsp40 family. First characterized for
its activities as an inhibitor of the key translation-mediator
eukaryotic initiation factor 2α (eIF2α)[ 39], P58IPK has since
been determined to play an essential role in preventing ER
stress [40, 41]. The mechanism by which P58IPK aﬀects ER
stress was determined to involve inhibition of PERK activa-
tion [42, 43], suggesting that P58IPK acts as a key mediator
of cotranslocational ER protein degradation; moreover, this
process is likely to contribute to ER homeostasis in stressed
cells. Mutant mouse strains with P58IPK gene deletion dis-
playedglucosuria,hyperglycemia,andhypoinsulinemia[44],
suggesting that P58IPK plays important roles in maintaining
normal glucose levels. P58IPK must enter the endoplasmic
reticulum through a translocon in order to perform its
protein synthesis and folding functions. Interestingly, P58IPK
can also prevent a polypeptide chain from entering the ER
through the translocon, thereby reducing protein loading of
the ER and protecting cells from the stress state [45, 46].
When polypeptide chains are excluded from the ER, they are
subject to degradation by the ubiquitin system. Accordingly,
it has been reported that ER stress can be experimentally
induced in rat pancreatic β cells by eliminating P58IPK as
a result, the islet cells of these rats experience signiﬁcant
apoptosis and develop diabetes [47].
We were the ﬁrst to investigate the eﬀect of P58IPK
on DR by performing extracorporeal experiments. Human
retinal capillary endothelial cells (HRCECs) were cultured
in vitro and transfected with a P58IPK overexpressing vector
or P58IPK RNA interference (RNAi) to suppress expression.
As expected, P58IPK expression was signiﬁcantly increased
in cells transfected with adeno-associated virus vector-
(rAAV2-) P58IPK (0.63 ± 0.02), as compared to those trans-
fected with pGIPZ-P58IPK RNAi (0.23 ± 0.01). P58IPK
expression was not diﬀerent between the control transfected
cells (rAAV2-GFP and pGIPZ-GFP). ER stress was induced
in the transfected cells by treating with tunicamycin and
changes in the expression of P58IPK were determined, along
with that of VEGF, core/emopamil-binding protein (C/EBP)
homologous protein (CHOP), ATF4, and GRP78. Apoptosis
levels were also determined for the P58IPK overexpressing
cells and suppressed cells. ER stress had no eﬀect on gene
expression in cells overexpressing P58IPK,a se v i d e n c e db y
no diﬀerence in expression levels of ATF-4, GRP78, CHOP,
and VEGF as compared to those in unstressed control cells.
However, the inhibitory eﬀect of P58IPK on the expressionExperimental Diabetes Research 5
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Figure 3: Associated functions of ER stress-related factors diﬀerentially expressed in diabetic retina in the ﬁrst (a) and third (b) month
after development of diabetes (numbers of proteins identiﬁed for each function are indicated). Expression levels were determined by
quantitativereal-timeRNApolymerasechainreactionmicroarraysandcomparedtothoseofnormalnondiabeticrats;diﬀerentialexpression
was designated if a gene was detected at 2-fold lower levels.
ofERstress-relatedfactorswassuppressedincellstransfected
with pGIPZ- P58IPK RNAi. Apoptosis was also found to be
signiﬁcantlyincreasedincellstransfectedwithpGIPZ-P58IPK
RNAi and not in those transfected with rAAV2-P58IPK [48].
We also investigated the eﬀects of P58IPK overexpression
on the retinas of rats with sustained high glucose. A rat
diabetic model was established by intraperitoneal injection
of streptozotocin. Overexpression of P58IPK was achieved by
intravitreal injection of puriﬁed recombinant rAAV2-P58IPK
or transfection into cultured rat retinal capillary endothe-
lial cells. Retinal vascular permeability was determined by
assessing the Evans Blue retinal leakage. To downregulate the
P58IPK level in cultured rat retinal capillary endothelial cells,
pGIPZP58IPK RNAi was introduced in these cells. Real-time
reverse transcription- (RT-) PCR and Western blot analyses
were performed to evaluate the mRNA and protein levels,
respectively, of CHOP, VEGF, and tumor necrosis factor-α
(TNF-α). Results showed that retinal blood vessel leakage
was signiﬁcantly decreased in diabetic rats overexpressing
P58IPK, as compared with the control diabetic rats. Both
mRNA and protein levels of CHOP, TNF-α, and VEGF
were remarkably reduced in the retinas of diabetic rats
overexpressing P58IPK. In vitro study further demonstrated
that overexpression of P58IPK led to the downregulation
of CHOP, TNF-α, and VEGF gene expression under high
glucose conditions, whereas RNAi suppression of P58IPK
enhanced the expression of CHOP, TNF-α, and VEGF [49].
Collectively, these studies indicated that P58IPK functions
includeprotectingtheintegrityofretinalvesselsandresisting
development and progression of DR. Its key role as a
stabilizing endoplasmic reticulum factor led us to presume
that P58IPK contributes to DR by reducing incidence of
ER stress through maintaining stability of the ER; these
studies are underway. Nonetheless, P58IPK appears to be a
particularly promising genetic target to develop therapy to
p r o t e c ta g a i n s tD R .
5.Which ERStress-RelatedFactors
ProtectagainstDR?
Research by our group and others are continuing to inves-
tigate the contribution of the full panel of ER stress-related
factors to DR. We established a high glucose rat model in
order to observe the expression changes of these ER stress-
related factors. At the same time, Ikesugi and colleagues and
Roybal and colleagues [28, 29] reported that in the early
stages of high glucose in rats the expressions of VEGF and
CHOP were upregulated, but the expressions of GRP78 and
ATF4 remained stable. Again, the animal experiment results
were consistent with those from the extracorporeal system
[50]. Therefore, the studies to determine exactly which ER
stress factors play critical roles in resisting DR and the
mechanisms by which they act are of clinical interest.
It is ultimately necessary to gain a comprehensive
understanding of the eﬀects of ER stress-related factors on
DR. To this end, we selected 89 factors from the entire
panel of known ER stress-related factors representing each
of the 11 subclasses of function in ER stress, [27]a n do n
the basis of relevant studies of ER stress from the literature
[28, 32, 51–69]. Custom-made real-time PCR chips based
on the rat sequences for these 89 genes were designed
(SABiosciences, Gaithersburg, Md, USA) and employed
for accurate detection of temporal expression changes of
these factors in the retina of high glucose rats. The results
indicated that 13 genes, including the P58IPK gene, were
signiﬁcantly down-regulated in the high glucose rat model
at 1 month old. In three-month-old high glucose rats,
1 2g e n e sw e r ed o w n r e g u l a t e d( Figure 3). In addition, we
found that three key signaling pathways of ER stress (PERK,
IRE1 and ATF6) were not activated in the early stage of
high glucose in these rats. This phenomenon is consistent
with our earlier research ﬁndings [50]. According to the
results of our gene chip studies, the ERAD pathway-related6 Experimental Diabetes Research
factors were of particular interest. The eﬀects of P58IPK and
ERAD in ER stress were discussed in this paper. Firstly,
both have eﬀects on maintaining functional balance of
the endoplasmic reticulum and in preventing ER stress.
P58IPK mediates the transport of new unfolded proteins
entering into the endoplasmic reticulum [45], while ERAD
degrades the unfolded proteins that have accumulated in the
endoplasmic reticulum. Removal (processing) of unfolded
proteinsfromtheendoplasmicreticulumiscrucialtoprevent
ER stress, and is a more direct control mechanism than
the transport modulation by P58IPK. Therefore, we have
theorized that overexpression of ERAD-related factors in the
retinamightbeabletoboosttheERADsignalingpathwaysto
a more robust level and prevent ER stress under high glucose
conditions and halt or slow down the progress of DR.
6. Perspectivesfor FutureStudies
Much like the information gleaned from studies to iden-
tify disease-susceptibility genes, data on disease-protective
genes provide the foundational knowledge by which our
understanding of human health is advanced and eﬀective
healthcare strategies are developed. If the pathological
mechanismofDRistheproverbial“blackbox”,thendeﬁning
the gene expression proﬁle of DR will represent a window
through which we may observe and assess the situations
inside of it. Using this idea as a guide to our own studies, we
have gained signiﬁcant insights into which ER stress-related
factors participate in the onset and pathogenic process of DR
and identiﬁed a promising target for DR treatment.
However, like most disease processes, DR involves many
signaling pathways and physiological factors. Cross-talk and
functional interactions among these factors certainly form
a complex and dynamic network structure. Each individual
gene that is characterized as having a protective role against
DReﬀectivelyrepresentsasinglenodeinthatentirenetwork.
Therefore, the collective analysis of the DR gene expression
proﬁle must be continued and augmented with studies to
understand the inﬂuence of clinical (comorbidities) and
nonphysiologic aspects (environmental factors).
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